Advanced Oxidation Protein Products and Advanced Glycation End Products in Children and Adolescents With Chronic Renal Insufficiency

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages 143-148

  Šebeková, Katarína ^a   Klenovicsová, Kristína ^b   Ferenczová, Juliana ^c   Hedvig, Juraj ^c   Podracká, L'udmila ^c   Heidland, August ^d  

^a Physics and Informatics   (Slovakia)

^b SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^c P J AFÁRIK UNIVERSITY   (Slovakia)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; PLASMA PROTEIN; SERUM ALBUMIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHILD; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INFANT; KIDNEY TRANSPLANTATION; MALE; OXIDATIVE STRESS; PRESCHOOL CHILD;

ADOLESCENT; ADULT; BLOOD PROTEINS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFANT; KIDNEY TRANSPLANTATION; MALE; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC; SERUM ALBUMIN;

EID: 84855169023     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.10.022     Document Type: Article

References (20)

1. Witko-Sarsat V., Friedlander M., Capeillere-Blandin C., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996, 49:1304-1313.
2. Witko-Sarsat V., Friedlander M., Nguyen K.T., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998, 161:2524-2532.
3. Furuya R., Kumagai H., Odamaki M., Takahashi M., Miyaki A., Hishida A. Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients. Nephron Clin Pract 2009, 112:c255-c261.
4. Yang X.B., Hou F.F., Wu Q., et al. Increased levels of advanced oxidation protein products are associated with atherosclerosis in chronic kidney disease. Zhonghua Nei Ke Za Zhi 2005, 44:342-346.
5. Iwao Y., Nakajou K., Nagai R., et al. CD36 is one of important receptors promoting renal tubular injury by advanced oxidation protein products. Am J Physiol Renal Physiol 2008, 295:F1871-F1880.
6. Guo Z.J., Niu H.X., Hou F.F., et al. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 2008, 10:1699-1712.
7. Shi X.Y., Hou F.F., Niu H.X., et al. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 2008, 149:1829-1839.
8. Li H.Y., Hou F.F., Zhang X., et al. Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. J Am Soc Nephrol 2007, 18:528-538.
9. Marsche G., Frank S., Hrzenjak A., et al. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists invivo. Circ Res 2009, 104:750-757.
10. Heidland A., Šebekova K., Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001, 38(4 suppl. 1):S100-S106.
11. Miyata T., Kurokawa K., van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int 2000, 76(suppl):S120-S125.
12. Šebeková K., Podracká L., Blažíček P., Syrová D., Heidland A., Schinzel R. Plasma levels of advanced glycation end products in children with renal disease. Pediatr Nephrol 2001, 16:1105-1112.
13. Misselwitz J., Franke S., Kauf E., John U., Stein G. Advanced glycation end products in children with chronic renal failure and type 1 diabetes. Pediatr Nephrol 2002, 17:316-321.
14. Kocak H., Gumuslu S., Ermis C., et al. Oxidative stress and asymmetric dimethylarginine is independently associated with carotid intima media thickness in peritoneal dialysis patients. Am J Nephrol 2008, 28:91-96.
15. Schwartz G.J., Brion L.P., Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin N Am 1987, 34:571-590.
16. Munch G., Keis R., Wessels A., et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997, 35:669-677.
17. Antolini F., Valente F., Ricciardi D., Baroni M., Fagugli R.M. Principal component analysis of some oxidative stress parameters and their relationships in hemodialytic and transplanted patients. Clin Chim Acta 2005, 358:87-94.
18. Kalousová M., Zima T., Tesar V., Lachmanová J. Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients. Blood Purif 2002, 20:531-536.
19. Descamps-Latscha B., Witko-Sarsat V., Nguyen-Khoa T., et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005, 45(1):39-47.
20. Kocak H., Gumuslu S., Sahin E., et al. Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients. Nephrology (Carlton) 2009, 14:273-280.